| __timestamp | Halozyme Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 5758000 |
| Thursday, January 1, 2015 | 29245000 | 8423000 |
| Friday, January 1, 2016 | 33206000 | 11986000 |
| Sunday, January 1, 2017 | 31152000 | 15215000 |
| Monday, January 1, 2018 | 10136000 | 15356000 |
| Tuesday, January 1, 2019 | 45546000 | 16660000 |
| Wednesday, January 1, 2020 | 43367000 | 52459000 |
| Friday, January 1, 2021 | 81413000 | 75061000 |
| Saturday, January 1, 2022 | 139304000 | 87221000 |
| Sunday, January 1, 2023 | 192361000 | 83779000 |
| Monday, January 1, 2024 | 159417000 |
Unleashing insights
In the competitive landscape of biopharmaceuticals, cost efficiency is a critical metric. From 2014 to 2023, Halozyme Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue. Halozyme's cost of revenue surged by approximately 747% over this period, peaking in 2023. In contrast, Supernus exhibited a more modest increase of around 135%, with a notable spike in 2020. This divergence highlights Halozyme's aggressive expansion strategy, while Supernus maintains a steadier growth trajectory. The data underscores the importance of strategic financial management in sustaining competitive advantage. As the industry evolves, these insights offer a glimpse into how companies navigate the balance between growth and cost efficiency.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Walgreens Boots Alliance, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Pharming Group N.V. and Supernus Pharmaceuticals, Inc.'s Expenses
Corcept Therapeutics Incorporated vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Supernus Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.